Beta
ManageSearchChatDiscover
351464

Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban

Article

Last updated: 29 Dec 2024

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

No enough information available in matter of
patient on Rivaroxaban a direct factor Xa
inhibitor specially in Saudi population. In
addition, patient with chronic kidney disease,
valvular atrial fibrillation or liver disease must
not be considered for such therapeutic change.
This study will be the first to give an idea about
current practice being used at anticoagulant
clinic and criteria used to choose patients were
switched to Rivaroxaban

DOI

10.21608/cvrepj.2022.351464

Volume

6

Article Issue

1

Related Issue

47292

Issue Date

2022-06-01

Receive Date

2024-04-23

Publish Date

2022-06-01

Print ISSN

2636-4204

Online ISSN

2636-4212

Article File

CVREPJ3514641654034400.pdf

PDF . 132.5kB

Link

https://cvrepj.journals.ekb.eg/article_351464.html

Detail API

https://cvrepj.journals.ekb.eg/service?article_code=351464

Order

351,464

Type

Abstracts

Type Code

3,139

Publication Type

Journal

Publication Title

Cardiovascular Research Prove Journal

Publication Link

https://cvrepj.journals.ekb.eg/

MainTitle

Efficacy and Safety and Mortality: Monitoring the patients on Rivaroxaban

Details

Type

Article

Created At

20 Dec 2024